Newsroom

  • March 20, 2019
    Oncorus Announces Four Presentations at AACR Annual Meeting 2019

    Oncorus Announces Four Presentations at AACR Annual Meeting 2019 — Oral presentation to highlight preclinical data supporting company’s lead oncolytic virus therapy clinical candidate, ONCR-177 — — Three poster presentations to showcase multiple, proprietary innovations underlying company’s local and systemic oncolytic virus platforms — CAMBRIDGE, Mass., March 20, 2019 – Oncorus, Inc., an oncolytic virus […]

    Learn More
  • November 28, 2018
    ONCORUS ANNOUNCES NOMINATION OF ONCR-177, A NEXT-GENERATION ONCOLYTIC VIRUS THERAPY CLINICAL CANDIDATE FOR MULTIPLE SOLID TUMOR INDICATIONS

    Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy Clinical Candidate for Multiple Solid Tumor Indications   –Oncorus to provide pipeline and business update at Piper Jaffray 30th Annual Health Care Conference– —ONCR-177 First-in-Human Trial Initiation Planned for 2019— —Company advancing next-generation oncolytic herpes simplex and synthetic viruses for local and systemic administration and […]

    Learn More
  • August 1, 2018
    ONCORUS, INC., NAMES INDUSTRY VETERAN TED ASHBURN AS NEW PRESIDENT AND CEO

    FOR IMMEDIATE RELEASE Oncorus®, Inc., Names Industry Veteran Ted Ashburn as new President and CEO – Company co-founder Mitch Finer named new Chairman of the Board –   Cambridge, MA, August 1, 2018 – Oncorus®, Inc., a biotechnology company developing a best-in-class platform of oncolytic viruses for the treatment of several types of cancer, today […]

    Learn More
  • March 15, 2018
    ONCORUS, INC., PRESENTS PRECLINICAL DATA ON NEXT-GENERATION ONCOLYTIC VIRUS PLATFORM AT AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2018 ANNUAL MEETING

    FOR IMMEDIATE RELEASE Oncorus®, Inc., Presents Preclinical Data on Next-Generation Oncolytic Virus Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting Cambridge, MA, March 15, 2018 – Oncorus®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types, today announced that preclinical data about […]

    Learn More
  • November 14, 2017
    ONCORUS, INC., TO PRESENT AT THE 29TH ANNUAL PIPER JAFFRAY HEALTHCARE CONFERENCE

    FOR IMMEDIATE RELEASE   Oncorus, Inc., to Present at the 29th Annual Piper Jaffray Healthcare Conference   Cambridge, MA, November 14, 2017 – Oncorus®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced that its […]

    Learn More
  • October 3, 2017
    ONCORUS, INC., NAMES CHRISTOPHE QUÉVA, PH.D., AS CHIEF SCIENTIFIC OFFICER

    FOR IMMEDIATE RELEASE  – Industry veteran brings extensive immuno-oncology experience and successful portfolio building track record –  – Company also announces two new senior appointments –    Cambridge, MA, October 3, 2017 – Oncorus, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive […]

    Learn More

Media Inquiries: media@oncorus.com

Top